Introduction
============

Despite the large-scale screening programs in developed countries, cervical cancer remains a major health concern in the United States, accounting for \>12,800 and 4,200 new diagnoses and deaths, respectively, in 2017([@b1-mco-0-0-1959]). In addition, cervical cancer is the second most common cause of death from cancer among women aged 20-39 years ([@b2-mco-0-0-1959]). Early cervical cancer (ECC), which can be treated with radical hysterectomy, has been reported to have 5-year survival rates of 88-97% after surgery ([@b3-mco-0-0-1959],[@b4-mco-0-0-1959]).

Various types of conventional radical surgery, such as radical hysterectomy, trachelectomy, and parametrectomy, remain the standard treatment for ECC (International Federation of Gynecology and Obstetrics stage I-IIA) ([@b5-mco-0-0-1959],[@b6-mco-0-0-1959]). According to the Querleu and Morrow classification, conventional radical hysterectomy (CRH) means type C2 hysterectomy. Following this procedure, the hypogastric nerve (sympathetic nerve), the pelvic splanchnic nerve (parasympathetic nerve), and the vesical branch of the pelvic plexus (both sympathetic and parasympathetic nerves) are damaged during the dissection of the uterosacral ligament, vesicouterine ligament and parametrium. These injuries are the leading cause of postoperative pelvic dysfunction, typically including bladder, sexual and colorectal dysfunction ([@b7-mco-0-0-1959],[@b8-mco-0-0-1959]).

As ECC has a high 5-year survival rate, the long-term quality of life of the patients is important. It is also important how quickly the pelvic dysfunction is restored. The concept of 'nerve-sparing' surgery was first described by Höckel *et al* ([@b9-mco-0-0-1959]) in 1998 as part of an effort to improve the oncological outcome of radical hysterectomy by extending the resection of parametrial tissue without further impairing pelvic autonomic nerve functions. Since then, this surgical procedure has been actively performed and studied, mainly by the Japanese research group ([@b9-mco-0-0-1959]). However, nerve-sparing radical hysterectomy (NSRH) remains controversial in gynecological oncology. Although this technique may have a positive impact on the quality of life of the patients, the heterogeneity of the technique itself is substantial and there is ongoing debate regarding the oncological outcome ([@b3-mco-0-0-1959],[@b4-mco-0-0-1959],[@b10-mco-0-0-1959]).

Although five systematic reviews with meta-analyses and three randomized controlled trials (RCTs) have been published to date, they are not sufficient to verify the efficacy and safety of NSRH in ECC ([@b4-mco-0-0-1959],[@b10-mco-0-0-1959]). In the present systematic review and meta-analysis, pooled data may provide evidence regarding both comparative effectiveness and safety between NSRH and CRH in ECC. The aim was to review the currently available relevant literature and compare morbidity, pelvic dysfunction and oncological outcomes between the two surgical methods.

Materials and methods
=====================

### Search strategy

The present systematic review and meta-analysis followed the recommendations of Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines ([@b17-mco-0-0-1959]). For this meta-analysis, the Cochrane Central Register of controlled Trials (CENTRAL), MedLine and Embase were searched for relevant studies published between 2000 and 2018, using the terms 'cervical AND cancer OR malignancy OR carcinoma' AND 'nerve AND sparing' AND 'radical AND hysterectomy'.

### Study selection and inclusion criteria

Published articles were included if they met the following criteria: i) Studies reporting data of patients affected by cervical cancer; ii) English language studies; iii) series including ≥20 patients and iv) studies reporting data of patients with comparison of clinical outcomes between NSRH and CRH. If there were duplicate studies, the studies that were published first or provided more information were included.

### Data extraction

Two authors (KHY, KSJ) independently extracted the data, and disagreements were re-evaluated by two other authors (YJH, CSE). Two reviewers (KHY, KSJ) worked independently, and examined the potential eligibility of all studies retrieved from the databases based on selection and exclusion criteria. The third and fourth reviewers (YJH, CSE) resolved inconsistencies between the first two reviewers through consensus and discussion. The data investigated were perioperative outcomes, quality of life indicators, progression-free survival (PFS) and overall survival (OS).

### Quality assessment

The questionnaire for methodological quality of the Cochrane Collaboration\'s Risk of Bias assessment tool was answered for each article to determine the risk of bias. The level of bias of the included studies was assessed based on the Cochrane Collaboration system ([@b18-mco-0-0-1959]). Furthermore, the quality of outcomes was rated using the Grading of Recommendations, Assessment, Development and Evaluation system ([@b19-mco-0-0-1959]). The meta-analyses were conducted using Review Manager software, version 5.3([@b20-mco-0-0-1959]), which is designed for conducting Cochrane reviews.

### Statistical analysis

Dichotomous outcomes eligible in each study are demonstrated as risk ratio (RR) with estimated 95% confidence interval (CI). Continuous outcomes are shown as the weighted mean difference (WMD) with 95% CI, which were calculated from mean, standard deviation (SD), P-value and sample size in each study. Heterogeneity was assessed using Higgins I^2^, evaluating the percentage of total variation across studies that was due to heterogeneity rather than chance. Thus, an I^2^ of \>50% was considered to reflect substantial heterogeneity, and thereby the random effects model using the DerSimonian and Laird method was used. The fixed effects model, using the Mantel-Haenszel method, was employed when I^2^ was ≤50%, indicating no heterogeneity. The Cochrane Review software (Review Manager version 5.3) was used in order to assess the heterogeneity of the included studies and to evaluate pooled results of the included investigations. The level of heterogeneity was studied for each comparison. On the basis of the level of heterogeneity, the random and fixed effects models were used to compare outcomes between groups. Random and fixed effects models were used as appropriate. Forest plots were created for each comparison and RR, WMD and 95% CI are presented; P-values \<0.05 were considered to indicate statistically significant differences.

Results
=======

### Eligible studies

A total of 211 studies were identified, and 26 duplicated articles were excluded. In addition, 153 studies, including non-cervical cancer (n=35), non-English language studies (n=27), case reports and reviewed articles (n=91), were excluded. After assessment of full-text articles for eligibility, an additional 9 studies were excluded due to the following criteria: Number of patients \<20 (n=5), no control group (n=2), and ineligible statistical information (n=2). Finally, 4 RCTs, 8 case control and 11 comparative cohort studies were included in the present meta-analysis. A total of 23 articles were selected for data extraction. Detailed information of study acquisition may be found in [Fig. 1](#f1-mco-0-0-1959){ref-type="fig"}.

### Study characteristics

A total of 23 articles were selected for inclusion in this meta-analysis, 4 of which were RCTs and the remaining 19 were case control or comparative cohort studies. Overall, 1,769 patients were included: 912 (50.8%) and 884 (49.2%) patients had undergone CRH and NSRH, respectively. The risk of bias was assessed for all studies. A summary of the included studies ([@b11-mco-0-0-1959],[@b21-mco-0-0-1959]) is presented in [Table I](#tI-mco-0-0-1959){ref-type="table"}.

### Study quality

All 23 studies included were retrospective. The risk of bias was deemed to be high in all the studies due to the lack of blinding of the participants or personnel and outcome assessors. Moreover, all studies were characterized by high risk of allocation bias. A detailed risk of bias assessment is described in [Fig. 2](#f2-mco-0-0-1959){ref-type="fig"}.

### Meta-analysis results

Outcomes included the following perioperative parameters: Mean operative time, mean estimated blood loss and length of hospital stay. Outcomes as an indicator of quality of life were as follows: Duration of postoperative catheter (days), urinary dysfunction, rectal dysfunction and sexual dysfunction. The analysis of oncological outcome was performed through radicality, PFS and OS. Radicality was measured by the resected parametrium and vagina. The operative time (WMD, 8.45 min; 95% CI: -2.79 to 19.67; P=0.14) did not differ statistically significantly between patients undergoing CRH and NSRH ([Fig. 3](#f3-mco-0-0-1959){ref-type="fig"}). As regards perioperative parameters, NSRH was found to be associated with lower intraoperative blood loss (WMD, -87.29 ml; 95% CI: -139.91 to -34.66; P=0.001) and a shorter length of hospital stay (WMD, -5.37 days; 95% CI: -8.08 to -2.67; P\<0.0001) in comparison with CRH.

Data on pelvic floor dysfunction rates are presented in [Fig. 4](#f4-mco-0-0-1959){ref-type="fig"}. Patients undergoing NSRH experienced lower urinary (RR=0.34; 95% CI: 0.18 to 0.63; P=0.0007), colorectal (RR=0.24; 95% CI: 0.13 to 0.45; P\<0.00001) and sexual (RR=0.27; 95% CI; 0.08 to 0.86; P=0.03) dysfunction rates compared with patients undergoing CRH ([Fig. 4A](#f4-mco-0-0-1959){ref-type="fig"}). In particular, a shorter duration of postoperative catheterization (WMD, -8.59 days; 95% CI: -12.17 to -5.02; P\<0.00001) was observed among patients undergoing NSRH compared with patients undergoing CRH ([Fig. 4B](#f4-mco-0-0-1959){ref-type="fig"}). Resected parametrial width was a favorable factor in patients with CRH (WMD, -0.78 cm; 95% CI: -1.45 to -0.11; P=0.02). This result suggests that NSRH is inferior to CRH in terms of radicality ([Fig. 5](#f5-mco-0-0-1959){ref-type="fig"}). The 5-year disease free survival (RR=0.98; 95% CI: 0.90 to 1.06; P=0.62) and 5-year OS (RR=0.97; 95% CI: 0.92 to 1.02; P=0.26) rates were similar between groups ([Fig. 6](#f6-mco-0-0-1959){ref-type="fig"}).

Discussion
==========

The present study was a systematic review and meta-analysis of the current evidence on the role of the nerve-sparing approach to surgical treatment for ECC, collecting data from studies comparing NSRH with CRH. Considering the heterogeneity between studies, we were able to obtain valuable data regarding pelvic dysfunction rate and oncological outcome. First, our findings supported the results of studies reporting that NSRH was associated with a shorter duration of postoperative catheterization compared with CRH. These findings indicated that bladder function recovered faster and the incidence of bladder dysfunction was lower compared with that of CRH when using the NSRH approach. Second, postoperative flatulence, constipation and fecal incontinence are the main manifestations of anorectal dysfunction, and the results are more favorable for NSRH compared with CRH. The negative effect of CRH on bowel function was also reported in other studies ([@b43-mco-0-0-1959]). Similarly, the nerve-sparing approach was associated with a lower rate of sexual dysfunction. There was no difference in operative time between the two groups. However, estimated blood loss and length of hospital stay were favorable for NSRH. In a meta-analysis with a non-randomized study, NSRH was reported to be associated with a longer operative time compared with CRH ([@b44-mco-0-0-1959]). Unlike our results, estimated blood loss and length of hospital stay were similar between the two groups in this non-randomized study.

The results of present systematic review and meta-analysis suggest that NSRH is associated with fewer complications and faster recovery of pelvic function compared with CRH. Therefore, the radicality and oncological outcome were compared between the two groups. Radicality was analyzed by resected parametrium width and vaginal length, and NSRH exhibited lower radicality compared with CRH. Liang *et al* investigated the safety of 163 ECC patients and observed a statistically significant reduction in the length of the resected parametrium and vagina in the NSRH group ([@b29-mco-0-0-1959]). The lower radicality *per se* may also be a concern. However, other studies have reported favorable results of less radical surgery in combination with neoadjuvant chemotherapy ([@b45-mco-0-0-1959]). There was no significant difference in the 5-year PFS and OS between NSRH and CRH. The reason for the less radical approach not affecting the oncological outcome may be explained by previous studies ([@b12-mco-0-0-1959],[@b36-mco-0-0-1959],[@b39-mco-0-0-1959]). Chen *et al* ([@b12-mco-0-0-1959]) analyzed the cardinal ligament tissue specimens of 12 and 13 patients undergoing NSRH and CRH, respectively, and found that, compared with CRH, fewer pelvic nerves were removed in NSRH during cardinal ligament dissection. In addition, they confirmed that the same number of blood and lymphatic vessels were eliminated with both approaches. The metastasis of cervical cancer occurs mainly through the blood vessels and the lymphatic system, whereas metastasis through the nerves is extremely rare, with only one such case reported to date ([@b46-mco-0-0-1959]). However, even this single case was one with advanced cervical cancer, rather than ECC. These results may clarify why oncological outcome did not differ between the two groups, and why the pelvic dysfunction rate was lower in the NSRH group.

However, only 4 RCTs were included in the evaluated studies, whereas the majority were case-control and comparative cohort studies. There was also heterogeneity between studies, and there was no level A evidence on this issue. However, the studies were well-conducted and the data extracted were sufficient to understand the impact of the nerve-sparing approach compared with CRH. Recently, Chinese study groups conducted larger studies ([@b28-mco-0-0-1959],[@b29-mco-0-0-1959],[@b47-mco-0-0-1959]), and a total of 172 patients (82, 60 and 30 patients, respectively) underwent NSRH. Lower pelvic dysfunction rate and improved safety were confirmed with the nerve-sparing approach in these studies.

There were certain limitations to the present study: i) As mentioned earlier, the first limitation of this meta-analysis was the considerable heterogeneity among the studies. There are inherent biases in the various-design papers included in the present study. Therefore, this must be taken into consideration when interpreting the results. The risk of bias of the included studies was systematically assessed, as seen in [Fig. 6](#f6-mco-0-0-1959){ref-type="fig"}. ii) There were several omitted data across different studies. Therefore, the results should be interpreted with caution. iii) The mean number of patients included in the reviewed studies was only 50 per group, which is relatively small. iv) RR rather than hazard ratio was used to assess survival outcomes. RR only measures the number of events and takes no account of when they occur; thus, it is suitable for measuring dichotomous outcomes, but less appropriate for analyzing time-to-event outcomes ([@b48-mco-0-0-1959]). When the total number of events reported for each study is used to calculate RR, the result is an estimate that is difficult to interpret. Although interpretation may be difficult, RRs can be calculated at specific time points, making estimates comparable and easier to interpret, at least at those time points.

In conclusion, the data collected in this systematic review and meta-analysis demonstrated that the nerve-sparing approach guarantees minimized risk of surgical-related pelvic dysfunction, while achieving a similar oncological outcome as CRH, supporting the preferred use of NSRH over CRH as a treatment for ECC patients. However, further RCTs should be conducted to establish the superiority and safety of NSRH in ECC.

Not applicable.

Funding
=======

The present study was supported by Dong-A University.

Availability of data and materials
==================================

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors\' contributions
=======================

SHL wrote the manuscript and analyzed the data. JWB, MH, YJC, JWP and SRO analyzed the data. SJK, SYC, JHY and YL collected the data. All authors have read and approved the final version of this manuscript for publication.

Ethics approval and consent to participate
==========================================

Not applicable.

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

![Flowchart of study selection process for the systematic review and meta-analysis.](mco-12-02-0160-g00){#f1-mco-0-0-1959}

![Risk of bias.](mco-12-02-0160-g01){#f2-mco-0-0-1959}

![Pooled results for operative time, blood loss and length of hospital stay. NSRH, nerve-sparing radical hysterectomy; CRH, conventional radical hysterectomy; SD, standard deviation; CI, confidence interval.](mco-12-02-0160-g02){#f3-mco-0-0-1959}
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###### 

Main characteristics of the included studies

  First author       Year   Study design   Evaluation   Study period   Patients, n   CRH, n   NSRH, n   (Refs.)
  ------------------ ------ -------------- ------------ -------------- ------------- -------- --------- -----------------------
  Bogani             2014   CC             PS           2004-2012      96            63       33        ([@b21-mco-0-0-1959])
  Ceccaroni          2012   CC             RS           1997-2009      56            31       25        ([@b22-mco-0-0-1959])
  Chen               2012   RCT            PS           NS             NS            NS       NS        ([@b12-mco-0-0-1959])
  Chen               2014   RCT            PS           NS             NS            NS       NS        ([@b23-mco-0-0-1959])
  Ditto              2011   CC             NS           NS             NS            NS       NS        ([@b25-mco-0-0-1959])
  Ditto              2018   CC             NS           NS             NS            NS       NS        ([@b26-mco-0-0-1959])
  van Gent           2017   CC             PS           1994-2005      246           124      122       ([@b27-mco-0-0-1959])
  Kuwabara           2000   CC             PS           1993-1994      37            18       19        ([@b28-mco-0-0-1959])
  Liang              2010   CC             PS           2006-2009      163           81       82        ([@b29-mco-0-0-1959])
  Liu                2016   CC             PS           2011-2012      120           60       60        ([@b30-mco-0-0-1959])
  Makowski           2014   CC             NS           2001-2012      73            53       20        ([@b31-mco-0-0-1959])
  Possover           2000   CC             PS           1997-1999      38            28       10        ([@b32-mco-0-0-1959])
  Querleu            2002   CC             RS           1991-1996      95            47       48        ([@b33-mco-0-0-1959])
  Raspagliesi        2006   CC             PS           NS             110           51       59        ([@b34-mco-0-0-1959])
  Raspagliesi        2017   CC             PS           2009-2016      83            36       47        ([@b35-mco-0-0-1959])
  Roh                2015   RCT            PS           2003-2005      86            40       46        ([@b36-mco-0-0-1959])
  Sakuragi           2005   CC             PS           2000-2002      27            5        22        ([@b37-mco-0-0-1959])
  Shi                2016   CC             RS           2003-2013      108           42       64        ([@b38-mco-0-0-1959])
  Skret-Magierlo     2010   CC             PS           2007-2008      20            10       10        ([@b39-mco-0-0-1959])
  van den Tillaart   2009   CC             PS           1994-1999      246           124      122       ([@b40-mco-0-0-1959])
                                                        2001-2005                                        
  Tseng              2012   CC             PS           2010-2011      30            12       18        ([@b41-mco-0-0-1959])
  Wu                 2010   RCT            PS           2007-2008      31            16       15        ([@b11-mco-0-0-1959])
  Yang               2016   CC             PS           2012-2015      76            38       38        ([@b42-mco-0-0-1959])

CC, case-control; PS, prospective study; RS, retrospective study; RCT, randomized controlled trial; NSRH nerve-sparing radical hysterectomy; CRH, conventional radical hysterectomy; NS, non-specified.
